Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing erosive esophagitis:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be increased as needed. Maximum recommended dose is 120 mg intravenously every 8 hours or 240 mg intravenously once daily.
## Pediatric Dosing
* **Erosive esophagitis (5 to 16 years):** 20 mg orally once daily for up to 8 weeks.
* **Erosive esophagitis (1 to <5 years):** 15 mg/m² orally once daily, not to exceed 40 mg daily, for up to 8 weeks.
* **Note:** Intravenous formulations are not typically recommended for pediatric patients unless oral administration is not possible. Dosing for pathological hypersecretory conditions in pediatric patients is less established and requires careful consideration and monitoring.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 40 mg orally or intravenously once daily.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term use of PPIs may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures, and vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Pantoprazole can decrease the absorption of drugs like ketoconazole, itraconazole, atazanavir, and nelfinavir.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole can inhibit CYP2C19, potentially affecting the metabolism of drugs like clopidogrel.
## Monitoring
* Monitor for improvement of GERD symptoms.
* Monitor for signs and symptoms of *Clostridium difficile* infection.
* Consider monitoring vitamin B12 levels with long-term therapy.
* Monitor electrolytes, especially in patients receiving concomitant diuretics.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* For intravenous administration, reconstitute and dilute according to manufacturer instructions.
* Long-term use should be regularly reassessed for the continued need for acid suppression.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical judgment. Always consult the most current prescribing information and relevant clinical guidelines for complete details, including indications, contraindications, warnings, precautions, adverse reactions, and drug interactions. Ensure doses are adjusted based on individual patient factors and local protocols.
